Payment overview · 2025
General Payments
$333.95
7 reported records · 4 companies
Healthcare provider profile · identity verified
Ronald Jc Fejeran, DO
Allopathic & Osteopathic Physicians|Internal Medicine · TAZEWELL, TN · NPI 1073518288
Verified facts
What the public records show
CMS Open Payments records show Ronald Jc Fejeran, DO received $333.95 in general payments during 2025 across 7 reported records.
AstraZeneca Pharmaceuticals LP accounted for 82.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $275.72 | 82.6% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.02 | 6.3% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $18.84 | 5.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.37 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $333.95 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $121.83 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $101.42 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $52.47 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.02 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 129 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
129 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1328 | 125 |
| Gabapentin | Gabapentin | 1228 | 125 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 743 | 132 |
| Atorvastatin Calcium | Atorvastatin Calcium | 662 | 108 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 482 | 44 |
| Omeprazole | Omeprazole | 368 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 354 | 48 |
| Benazepril Hcl | Benazepril Hcl | 311 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 292 | 48 |
| Metformin Hcl | Metformin Hcl | 287 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 285 | 55 |
| Diazepam | Diazepam | 259 | 25 |
| Lisinopril | Lisinopril | 253 | 40 |
| Oxycodone Hcl | Oxycodone Hcl | 251 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 232 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 201 | 44 |
| Furosemide | Furosemide | 189 | 36 |
| Clonazepam | Clonazepam | 185 | 20 |
| Alendronate Sodium | Alendronate Sodium | 171 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 164 | 29 |
| Alprazolam | Alprazolam | 162 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 157 | 29 |
| Ezetimibe | Ezetimibe | 154 | 26 |
| Atenolol | Atenolol | 153 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 149 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 146 | 33 |
| Potassium Chloride | Potassium Chloride | 135 | 23 |
| Losartan Potassium | Losartan Potassium | 133 | 24 |
| Sertraline Hcl | Sertraline Hcl | 133 | 28 |
| Pregabalin | Pregabalin | 132 | 14 |
| Simvastatin | Simvastatin | 130 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 129 | 39 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 129 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 129 | 12 |
| Ozempic | Semaglutide | 128 | 15 |
| Vascepa | Icosapent Ethyl | 126 | 28 |
| Ondansetron Odt | Ondansetron | 122 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 119 | 18 |
| Morphine Sulfate Er | Morphine Sulfate | 115 | 11 |
| Glipizide Er | Glipizide | 98 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 98 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 98 | 22 |
| Famotidine | Famotidine | 97 | 16 |
| Trazodone Hcl | Trazodone Hcl | 93 | 19 |
| Methotrexate | Methotrexate Sodium | 91 | 15 |
| Buspirone Hcl | Buspirone Hcl | 88 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 84 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 83 | 14 |
| Prednisone | Prednisone | 80 | 55 |
| Tramadol Hcl | Tramadol Hcl | 79 | 12 |
| Spiriva Respimat | Tiotropium Bromide | 76 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 75 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 74 | 14 |
| Carvedilol | Carvedilol | 73 | 14 |
| Eliquis | Apixaban | 70 | suppressed |
| Spironolactone | Spironolactone | 68 | 14 |
| Warfarin Sodium | Warfarin Sodium | 64 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 62 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 61 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 11 |
| Jardiance | Empagliflozin | 59 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 58 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 14 |
| Meloxicam | Meloxicam | 57 | 23 |
| Donepezil Hcl | Donepezil Hcl | 56 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 56 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 55 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 53 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 11 |
| Chlorthalidone | Chlorthalidone | 49 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 49 | 13 |
| Azithromycin | Azithromycin | 46 | 38 |
| Topiramate | Topiramate | 46 | suppressed |
| Vraylar | Cariprazine Hcl | 44 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 43 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 42 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 41 | suppressed |
| Myrbetriq | Mirabegron | 41 | suppressed |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Tradjenta | Linagliptin | 40 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 20 |
| Qvar Redihaler | Beclomethasone Dipropionate | 38 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 31 |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Cefdinir | Cefdinir | 36 | 26 |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 33 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 31 | suppressed |
| Glimepiride | Glimepiride | 31 | suppressed |
| Verapamil Er | Verapamil Hcl | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Creon | Lipase/Protease/Amylase | 29 | suppressed |
| Folic Acid | Folic Acid | 28 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 28 | suppressed |
| Cephalexin | Cephalexin | 26 | 18 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Nateglinide | Nateglinide | 25 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Nabumetone | Nabumetone | 23 | suppressed |
| Cholestyramine Light | Cholestyramine | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Roflumilast | Roflumilast | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | 13 |
| Glipizide | Glipizide | 20 | suppressed |
| Nystatin | Nystatin | 20 | 14 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 20 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 19 | suppressed |
| Allopurinol | Allopurinol | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Movantik | Naloxegol Oxalate | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Xtampza Er | Oxycodone Myristate | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 12 |
| Irbesartan | Irbesartan | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Pure Comfort Alcohol Pad | Alcohol Antiseptic Pads | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 12 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Toviaz | Fesoterodine Fumarate | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Flovent Hfa | Fluticasone Propionate | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $333.95 · 7 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, FARXIGA, Ohtuvayre, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error